Xilio Therapeutics (NASDAQ:XLO) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Xilio Therapeutics (NASDAQ:XLO) released its quarterly earnings data on Tuesday. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02, Zacks reports.

Xilio Therapeutics Stock Performance

NASDAQ XLO opened at $0.84 on Tuesday. The firm has a market capitalization of $37.14 million, a P/E ratio of -0.49 and a beta of -0.38. The stock has a 50-day simple moving average of $0.95 and a two-hundred day simple moving average of $0.94. Xilio Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $1.93.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.